MENU
+Compare
ESPR
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$1.82
Change
-$0.03 (-1.62%)
Capitalization
495.94M

ESPR Esperion Therapeutics Forecast, Technical & Fundamental Analysis

a developer of biopharmaceutical products

ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ESPR with price predictions
Feb 18, 2025

ESPR's Indicator enters downward trend

The Aroon Indicator for ESPR entered a downward trend on February 18, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 265 similar instances where the Aroon Indicator formed such a pattern. In of the 265 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ESPR's RSI Indicator exited the oversold zone, of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where ESPR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on February 13, 2025. You may want to consider a long position or call options on ESPR as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ESPR just turned positive on February 12, 2025. Looking at past instances where ESPR's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ESPR advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .

ESPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (59.679). P/E Ratio (0.000) is within average values for comparable stocks, (89.540). ESPR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.913). Dividend Yield (0.000) settles around the average of (0.120) among similar stocks. P/S Ratio (2.473) is also within normal values, averaging (19.827).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ESPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ESPR is expected to report earnings to fall 7.73% to -13 cents per share on February 27

Esperion Therapeutics ESPR Stock Earnings Reports
Q4'24
Est.
$-0.14
Q3'24
Beat
by $0.03
Q2'24
Missed
by $0.17
Q1'24
Beat
by $0.29
Q4'23
Missed
by $0.03
The last earnings report on November 07 showed earnings per share of -15 cents, beating the estimate of -17 cents. With 1.97M shares outstanding, the current market capitalization sits at 495.94M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceutical products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3891 Ranchero Drive
Phone
+1 734 887-3903
Employees
240
Web
https://www.esperion.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL245.55-0.28
-0.11%
Apple
BTC.X96258.000000-319.757800
-0.33%
Bitcoin cryptocurrency
SPY599.94-10.44
-1.71%
SPDR® S&P 500® ETF Trust
GME26.42-0.62
-2.29%
GameStop Corp
TSLA337.80-16.60
-4.68%
Tesla

ESPR and Stocks

Correlation & Price change

A.I.dvisor tells us that ESPR and EVO have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and EVO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+0.54%
EVO - ESPR
26%
Poorly correlated
+1.09%
PAHC - ESPR
25%
Poorly correlated
+0.19%
ALKS - ESPR
24%
Poorly correlated
+0.03%
OGI - ESPR
23%
Poorly correlated
+7.09%
TEVA - ESPR
23%
Poorly correlated
+1.97%
More